Table 3.
Gene symbol | Gene name | Validated miRNA target(s) | Predicted miRNA target | Altered in pregnancy pathologies | Altered by folate status |
---|---|---|---|---|---|
MYC | v‐myc myelocytomatosis viral oncogene homolog (avian) |
|
↑mRNA in FGR placenta [25] | ↑ in liver of folate‐deficient rat model 26 | |
ZEB 2 | zinc finger E‐box binding homeobox 2 |
|
34b‐5p | ↓ uterine tissue mouse model of PTB 31 | |
CDK6 | Cyclin‐dependent kinase 6 | 34b‐5p |
|
Placental expression positively correlates with birthweight 48 | |
VEGF A | Vascular endothelial growth factor A | 34b‐5p | 141‐3p | ↑ in FGR placenta 27 | ↑ or ↓ in folate deficient cells 28 |
BCL2 | B‐cell CLL/lymphoma 2 | 34b‐5p |
|
↑ in FGR/PE placenta 29 | |
BCL2L11 | BCL2‐like 11 (apoptosis facilitator, BIM) | 222‐3p |
|
↑ in FGR placenta 29 | ↑ with folate deficiency 28 |
CDKN1B | Cyclin‐dependent kinase inhibitor 1B (p27, Kip1) | 222‐3p |
|
↑ in PE placenta 53 | ↑ with folate deficiency 28 |
CDKN1C | Cyclin‐dependent kinase inhibitor 1C (p57, Kip2) | 222‐3p | ↑ in PE/FGR placenta 25, 53 | ↑ with folate deficiency 28 | |
TP53 | Tumor protein p53 | 222‐3p |
|
↑ in FGR placenta 30 | ↑ and ↓ with folate deficiency 28 |
ZEB 1 | Zinc finger E‐box binding homeobox 1 | 141‐3p | ↓ in uterine tissue mouse model of PTB 31 | ||
IGF2 | Insulin like growth factor 2 | 141‐3p | Placental specific K/O mouse models have FGR pups 32 |
Experimentally validated and putative targets of miRNAs, and association with folate deficiency and/or pregnancy complications.
FGR, fetal growth restriction; IBC, individualized birthweight centile; K/O, knock‐out; PE, preeclampsia; PTB, preterm birth.